News

Hosted on MSN3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...
Yahoo Finance3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease - Yahoo Finance
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) oral Fabhalta (iptacopan) for adults with C3 glomerulopathy (C3G) to reduce proteinuria (protein in the ...
Benzinga.com11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - Novartis (NYSE:NVS) - Benzinga
Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.
Reuters11mon
US FDA approves Novartis' kidney disease drug | Reuters
US FDA approves Novartis' kidney disease drug. By Sriparna Roy. August 7, 2024 10:29 PM UTC Updated August 7, 2024. The logo of Swiss drugmaker Novartis is pictured at the ...
Nasdaq3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
C3G is a progressive and ultra-rare kidney disease that is typically diagnosed in young adults and often progresses to kidney failure. Per NVS, this is the first and only treatment approved for ...
AOL11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - AOL
On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...
Benzinga.com3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease - Novartis (NYSE:NVS) - Benzinga
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.